← All trials
NCT05398055
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 12, 2022
- Primary completion
- Dec 31, 2025
- Completion date
- Dec 31, 2025
- First posted
- May 31, 2022
- Last posted
- May 31, 2022
- Enrollment
- 86
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Hospital General de MexicaliLead sponsor
- Hospital General de MexicaliOverall official - principal investigator
- Hospital General de MexicaliReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.